HeartSciences Inc. (HSCS) is a Nasdaq-listed micro-cap medical technology company that applies artificial intelligence to electrocardiograms (ECG), through its MyoVista wavECG device and MyoVista Insights cloud platform. The stock trades around $4.36, yet a small group of analysts carries price targets far above that level — raising a straightforward question for investors: can HSCS reach $10?
Coverage of HSCS is thin. Two current, attributable targets were reviewed. Ascendiant Capital analyst Lucas Ward lowered his target from $9 to $8 on March 24, 2026, while maintaining a Buy rating. Maxim Group has held a $12 target, reiterating its Buy recommendation. The arithmetic mean of these two figures is $10, and the range spans $8 to $12 — a 50% spread that underscores how uncertain the path forward is for such an early-stage company.
Both analysts frame the opportunity around the MyoVista device complementing the MyoVista Insights software rollout and expected FDA approval of the first diagnostic algorithm. Ascendiant has noted the scale of the U.S. ECG market — over 100 million tests annually — as a key part of its thesis. The divergence between an $8 and a $12 target reflects different assumptions about regulatory timing, commercial ramp, and the pace at which revenue can convert from pilot-stage to meaningful.
HSCS last traded near $4.36, with a market capitalization of roughly $21 million. The stock has been exceptionally volatile, with a 52-week range from about $1.63 to above $5. Moving from $4.36 to $10 implies a gain of approximately 129% — a very large move that would require not just favorable news, but a fundamental re-rating of the company.
The path would most likely depend on regulatory milestones. HeartSciences generates only minimal revenue — roughly $4,500 in trailing twelve-month revenue — and posted a net loss near $10.3 million over the same period. Analysts' targets therefore look through current losses and anticipate a transition toward recurring software revenue and device sales once regulatory clearance is secured and distribution scales.
HSCS trades well off its 52-week low near $1.63 and has recently tested levels above $5. The stock's thin float and heavy daily swings — with intraday ranges spanning from roughly $3.43 to $6.47 — make conventional support and resistance zones less reliable. The $5 area represents a notable prior ceiling, while a sustained move toward $10 would require breaking well beyond the stock's established multi-year trading band. Psychologically, the $5 and then $10 levels are the most obvious markers on any upward trajectory.
Analyst price targets generally reflect a research horizon of about 12 months, though the specific horizon for these two firms is not disclosed. Investors focused on the $10 target should watch the FDA decision on the first diagnostic algorithm, the company's quarterly cash position and any new financing, Nasdaq listing-compliance updates, and early signs of commercial traction in the MyoVista Insights rollout. Any upward or downward analyst revisions, particularly from Ascendiant or Maxim Group, would also signal how the thesis is evolving.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap like HSCS, where price action can change rapidly, such tools can help traders discover opportunities, monitor positions, and spot changing trends more efficiently than manual screening alone.
The $10 target for HeartSciences is a calculated average of two analyst targets — Ascendiant's $8 and Maxim Group's $12 — rather than an independently published consensus. It implies roughly 129% upside from the current price, a very large move achievable only through a sequence of successful regulatory, financial, and commercial milestones. Support rests on FDA clearance and the MyoVista product suite, while pre-revenue status, a thin cash position, and listing-compliance concerns are substantial obstacles. The wide $8-to-$12 range reflects genuine disagreement, and reaching the higher end would demand execution that has not yet been demonstrated. Investors should treat the target as an analyst-derived reference point, not a forecast, and watch the regulatory timeline and balance sheet closely.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that HSCS and HSDT have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HSCS and HSDT's prices will move in lockstep.
| Ticker / NAME | Correlation To HSCS | 1D Price Change % | ||
|---|---|---|---|---|
| HSCS | 100% | +13.74% | ||
| HSDT - HSCS | 32% Poorly correlated | +1.29% | ||
| PSNL - HSCS | 22% Poorly correlated | -0.25% | ||
| MYO - HSCS | 21% Poorly correlated | N/A | ||
| MBOT - HSCS | 21% Poorly correlated | -0.78% | ||
| QSI - HSCS | 21% Poorly correlated | +6.03% | ||
More | ||||
| Ticker / NAME | Correlation To HSCS | 1D Price Change % |
|---|---|---|
| HSCS | 100% | +13.74% |
| Medical/Nursing Services industry (139 stocks) | -0% Poorly correlated | -0.31% |
| Health Services industry (240 stocks) | -1% Poorly correlated | -0.00% |